ライブラリ登録: Guest
Begell Digital Portal Begellデジタルライブラリー 電子書籍 ジャーナル 参考文献と会報 リサーチ集
Critical Reviews™ in Therapeutic Drug Carrier Systems
インパクトファクター: 2.9 5年インパクトファクター: 3.72 SJR: 0.736 SNIP: 0.551 CiteScore™: 2.43

ISSN 印刷: 0743-4863
ISSN オンライン: 2162-660X

巻:
巻 37, 2020 巻 36, 2019 巻 35, 2018 巻 34, 2017 巻 33, 2016 巻 32, 2015 巻 31, 2014 巻 30, 2013 巻 29, 2012 巻 28, 2011 巻 27, 2010 巻 26, 2009 巻 25, 2008 巻 24, 2007 巻 23, 2006 巻 22, 2005 巻 21, 2004 巻 20, 2003 巻 19, 2002 巻 18, 2001 巻 17, 2000 巻 16, 1999 巻 15, 1998 巻 14, 1997 巻 13, 1996 巻 12, 1995

Critical Reviews™ in Therapeutic Drug Carrier Systems

DOI: 10.1615/CritRevTherDrugCarrierSyst.v18.i3.10
34 pages

Immunoisolation Cell Therapy for CNS Diseases

Dwaine F. Emerich
Department of Neuroscience, Alkermes, Inc, 64 Sidney Street, Cambridge MA 02139
Shelly R. Winn
Department of Surgery, Oregon Health Sciences University, 3181 S.W. Sam Jackson Park Road, Portland OR 97201

要約

Delivery of potentially therapeutic drugs to the brain is hindered by the blood-brain barrier (BBB), which restricts the diffusion of drugs from the vasculature to the brain parenchyma. One means of overcoming the BBB is with cellular implants that produce and deliver therapeutic molecules directly into the CNS region of interest. In this paper we describe the current status of one iteration of cell-based therapy that uses xenogeneic cells encased within a selectively permeable polymeric membrane; this is known as immunoisolation. For the purposes of this review, cell immunoisolation for treating CNS diseases is presented in terms of device configurations, membrane manufacturing, characterization in relevant preclinical model systems, and the current status of clinical trials.